Author： Huilgol Nagraj G.
Publisher： Informa Healthcare
ISSN： 1464-5157
Source： International Journal of Hyperthermia, Vol.22, Iss.5, 2006-08, pp. : 391-397
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Purpose : Arsenic trioxide [ATO] is a pluripotent drug with potentials to have pro-oxidant, angiogenesis inhibitor, flow inhibitor and radiation sensitizer properties. Methods : The present study is a Phase I trial to assess the safety of ATO in advanced or recurrent head and neck cancer treated with radiation and hyperthermia. Patients received ATO at 10, 20 and 30mg per week a day prior to hyperthermia. Results : It was assumed that vascular collapse would be complete by 24h. Administration of ATO at 20mg was safe with no toxicity due to ATO. No amplification of toxicities due to radiation or hyperthermia was evident. Patients without prior treatment showed better response. A total of 11 patients were included in this Phase I study. Conclusions : Patients who received 30mg of ATO weekly showed non-serious acute toxicities. No further escalation of dose was attempted.
Related content
Access to resources
Recommend
By Larsen Susanne Serup-Hansen Eva Andersen Lisbeth J. Lindeløv Birgit McCulloch Tine Adimi Parvin Bastholt Lars
Acta Oncologica, Vol. 46, Iss. 3, 2007-01 ,pp. :
By Vujaskovic Zeljko Kim Dong W. Jones Ellen Lan Lan Mccall Linda Dewhirst Mark W. Craciunescu Oana Stauffer Paul Liotcheva Vlayka Betof Allison Blackwell Kimberly
International Journal of Hyperthermia, Vol. 26, Iss. 5, 2010-08 ,pp. :
By Wong R.K.W. Jones G.W. Sagar S.M. Babjak A.-F. Whelan T.
International Journal of Radiation Oncology*Biology*Physics, Vol. 57, Iss. 2, 2003-10 ,pp. :